Seeking Alpha

Dr. Paul Nunzio...'s  Instablog

Dr. Paul Nunzio DeSantis, Pharm.D
Send Message
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation... More
My company:
Alpha BioPharma Advisers
My blog:
An Evidence-Driven Rebuttal To Morgan Stanley & Goldman Sachs Bearish Thesis On Gilead Sciences (GILD)
My book:
An Evidence-Driven Rebuttal To Morgan Stanley & Goldman Sachs Bearish Thesis On Gilead Sciences (GILD)
  • Sovaldi And GILD 2Q $4.1B Possible, $3.5B Minimum 2 comments
    Jul 18, 2014 11:20 AM | about stocks: GILD

    Updated Sovaldi Model shows $4.1B in Sales, translating into $6.5Bnet prouct REVS, and $1.975 in earnings. $3.5B in Sovaldi sales appears to be the minimum possible, IMS data show $2.9B, but only captured 0.88 of sales last qtr, adjusting for that factor, plus ex-US sales, inventory build, and V.A. adding Sovaldi in April to formulary, additional access to Sovaldi from new state Medicaid programs, and correctional systems, we calculate $4.1B for our model.

    Disclosure: The author is long GILD.

    Themes: earnings, estimate revision Stocks: GILD
Back To Dr. Paul Nunzio DeSantis, Pharm.D's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • Jack Hutchison
    , contributor
    Comments (430) | Send Message
     
    Dr. Paul,

     

    Your projections are less bullish than Barron's, predicting $2.25. Nevertheless, a 400% increase in earnings ain't too shabby. Maybe the stock will pop this time.

     

    Jack
    18 Jul 2014, 12:49 PM Reply Like
  • Dr. Paul Nunzio DeSantis, P...
    , contributor
    Comments (336) | Send Message
     
    Author’s reply » Im probably higher on the Sovaldi sales set. no? they are higher than $4.1B???!! I increased SGA expense, and R&D expense is why my EPS is lower at $1.975
    18 Jul 2014, 02:16 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.